Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors

Cancer Science

Volumn 103, Issue 3, 2012, Pages 535-541

  Fang, Jun ^a   Qin, Haibo ^a   Nakamura, Hideaki ^a   Tsukigawa, Kenji ^a   Shin, Takashi ^a   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARBON MONOXIDE; EVANS BLUE; HEME OXYGENASE 1; HEMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; EXTRAVASATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR BLOOD FLOW; ANIMAL; CAPILLARY PERMEABILITY; EXPERIMENTAL NEOPLASM; METABOLISM; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CARBON MONOXIDE; HEME OXYGENASE-1; MALE; MICE; NEOPLASMS, EXPERIMENTAL; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84874098069     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02178.x     Document Type: Article

References (49)

1. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98: 1108-17.
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986; 46: 6387-92.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
4. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
5. Maeda H, Matsumura Y, Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988; 263: 16051-4.
6. Matsumura Y, Kimura M, Yamamoto T, Maeda H. Involvement of the kiningenerating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988; 79: 1327-34.
7. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998; 58: 159-65.
8. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 331-4.
9. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
10. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
11. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001; 92: 439-51.
12. Suzuki M, Takahashi T, Sato T. Medial regression and its functional significance in tumor-supplying host arteries. A morphometric study of hepatic arteries in human livers with hepatocellular carcinoma. Cancer 1987; 59: 444-50.
13. Skinner SA, Tutton PJ, O'Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990; 50: 2411-7.
14. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984; 44: 2115-21.
15. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 47-61.
16. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2010; 63: 136-51.
17. Suzuki M, Hori K, Abe Z, Asito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663-9.
18. Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 975-80.
19. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 2009; 39: 756-66.
20. Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 2009; 100: 2426-30.
21. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 2004; 9: 27-35.
22. Doi K, Akaike T, Fujii S et al. Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 1999; 80: 1945-54.
23. Fang J, Sawa T, Akaike T et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003; 63: 3567-74.
24. Tanaka S, Akaike T, Fang J et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br J Cancer 2003; 88: 902-9.
25. Schacter BA. Heme catabolism by heme oxygenase: physiology, regulation, and mechanism of action. Semin Hematol 1988; 25: 349-69.
26. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988; 2: 2557-68.
27. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127.
28. Nakao A, Kaczorowski DJ, Wang Y et al. Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant 2010; 29: 544-53.
29. Nakao A, Choi AM, Murase N. Protective effect of carbon monoxide in transplantation. J Cell Mol Med 2006; 10: 650-71.
30. Fang J, Qin H, Seki T et al. Therapeutic potential of pegylated hemin for ROS-related diseases via induction of heme oxygenase-1: results from a rat hepatic ischemia/reperfusion injury model. J Pharmacol Exp Ther 2011; 339: 779-89.
31. Drummond GS, Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxygenase. Proc Natl Acad Sci USA 1981; 78: 6466-70.
32. Serfass L, Burstyn JN. Effect of heme oxygenase inhibitors on soluble guanylyl cyclase activity. Arch Biochem Biophys 1998; 359: 8-16.
33. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 2008; 8: 21-32.
34. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13.
35. Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.
36. Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009; 61: 1117-20.
37. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agentincorporating polymer micelles. Cancer Sci 2009; 100: 572-9.
38. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010; 21: 797-802.
39. Maeda H. Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J Control Release 2010; 142: 296-8.
40. Otterbein LE, Bach FH, Alam J et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6: 422-8.
41. Lin HH, Lai SC, Chau LY. Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. J Biol Chem 2011; 286: 3829-38.
42. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
43. Johnson FK, Johnson RA. Carbon monoxide promotes endothelium dependent constriction of isolated gracilis muscle arterioles. Am J Physiol Regul Integr Comp Physiol 2003; 285: R536-41.
44. Lamon BD, Zhang FF, Puri N, Brodsky SV, Goligorsky MS, Nasjletti A. Dual pathways of carbon monoxide-mediated vasoregulation: modulation by redox mechanisms. Circ Res 2009; 105: 775-83.
45. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
46. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008; 117: 231-41.
47. Ferrando M, Gueron G, Elguero B et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011; 14: 467-79.
48. Sunamura M, Duda DG, Ghattas MH et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6: 15-24.
49. Miyake M, Fujimoto K, Anai S et al. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep 2011; 25: 653-60.